Login Register Cart 0
Generic placeholder image

Current Chromatography

Editor-in-Chief

ISSN (Print): 2213-2406
ISSN (Online): 2213-2414

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Impurities Present in Cardiovascular Active Substances and Medicinal Products: A Pharmacopoeial Perspective

Author(s): Arvind K. Sharma*, Faraat Ali*, Anuj Prakash and Ramesh K. Goyal

Volume 9, Issue 1, 2022

Published on: 10 August, 2022

Article ID: e280722207051 Pages: 15

DOI: 10.2174/2213240609666220728091253

Price: $65

conference banner
Abstract

The quality of drugs is a major concern for drug regulatory authorities and other stakeholders across the globe. Recently, drug regulatory authorities across the globe are facing a challenge in controlling the purity of cardiovascular (CVS) drugs for human use, especially drugs from the Angiotensin Receptor Blocker family, such as Valsartan. The present article aims to provide comprehensive knowledge on how pharmacopeias worldwide play a key role in ensuring the quality of active pharmaceutical ingredients (API) and finished pharmaceutical products (FPPs). In this article, the focus is on comprehensive information regarding pharmaceutical impurities, separation strategies, relevant regulatory guidelines to control impurities, and their acceptable limits, particularly with respect to cardiovascular active drug substances and drug formulations for human use.

Keywords: Pharmaceutical sciences, pharmacopoeia, cardiovascular drugs, pharmaceutical impurities, NDMA, API.

[1]
Mensah, G.A.; Roth, G.A.; Fuster, V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J. Am. Coll. Cardiol., 2019, 74(20), 2529-2532.
[http://dx.doi.org/10.1016/j.jacc.2019.10.009] [PMID: 31727292]
[2]
Newman, C.; Ajay, V.S.; Srinivas, R.; Bhalla, S.; Prabhakaran, D.; Banerjee, A. Drugs for cardiovascular disease in India: Perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis. J. Pharm. Policy Pract., 2016, 9(1), 16.
[http://dx.doi.org/10.1186/s40545-016-0065-7] [PMID: 27141309]
[3]
Nayak, M.K. Recent drug development approaches in thrombosis, stroke and other cardiovascular diseases. Curr. Pharm. Des., 2019, 25(38), 4039-4040.
[http://dx.doi.org/10.2174/138161282538191217151815] [PMID: 31889483]
[4]
Misra, B.; Thakur, A.; Mahata, P.P. Pharmaceutical impurities: A review. Int. J. Pharm. Sci. Rev. Res., 2015, 5(07), 232-239.
[http://dx.doi.org/10.7439/ijpc]
[5]
Indian Pharmacopoeia, Indian Pharmacopoeia Commission Ghaziabad; Ministry of Health & Family Welfare, Government of India, 2018.
[6]
Dhangar, K.R.; Jagtap, R.B.; Surana, S.J.; Shirkhedkar, A.A. Impurity profiling of drugs towards safety and efficacy: Theory and practice. J. Chil. Chem. Soc., 2017, 62(2), 3543-3557.
[http://dx.doi.org/10.4067/S0717-97072017000200024]
[7]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH guidelines: Quality guidelines. 2020. Available from: https://www.ich.org/page/quality-guidelines
[8]
U.S. Food and Drug Administration. M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk: Guidance for Industry. Available from: https://www.fda.gov/media/85885/download (Accessed on: April 03, 2020).
[9]
Review of world pharmacopoeias. In: International Meeting of World Pharmacopoeias, World Health Organization, Working document QAS/12.512/Rev.1; Geneva, 2013.
[10]
Uddin, M.S.; Mamun, A.A.; Akter, N.; Sarwar, M.S.; Rashid, M.; Amran, M.S. Pharmacopoeial standards and specifications for pharma-ceutical oral liquid preparations. Arch. Curr. Res. Int., 2016, 3(2), 1-12.
[http://dx.doi.org/10.9734/ACRI/2016/22675]
[11]
British Pharmacopoeia; Medicines and Healthcare products Regulatory Agency: London, 2020.
[12]
Council of Europe. European Pharmacopoeia: Background- mission. Available from: https://www.edqm.eu/en/European-Pharmacopoeia-Background-Mission (Accessed on: September 28, 2020).
[13]
Council of Europe. Available from: https://www.edqm.eu/sites/default/files/01_schedule_2019_portrait.pdf
[14]
United States Pharmacopeia. Available from: https://qualitymatters. usp.org/what-us-pharmacopeia
[15]
Vivekanandan, K.; Prakash, J.; Muthusamy, K.; Singh, G.N. Quality standards and current status of ophthalmic formulations in indian pharmacopoeia and national formulary of India. Ther. Innov. Regul. Sci., 2014, 48(3), 386-392.
[http://dx.doi.org/10.1177/2168479013513455] [PMID: 30235542]
[16]
WHO Information note update on nitrosamine impurities. 2014.
[17]
Parr, M.K.; Joseph, J.F. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. J. Pharm. Biomed. Anal., 2019, 164, 536-549.
[http://dx.doi.org/10.1016/j.jpba.2018.11.010] [PMID: 30458387]
[18]
Masada, S.; Tsuji, G.; Arai, R.; Uchiyama, N.; Demizu, Y.; Tsutsumi, T.; Abe, Y.; Akiyama, H.; Hakamatsuka, T.; Izutsu, K.I.; Goda, Y.; Okuda, H. Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products. Sci. Rep., 2019, 9(1), 11852.
[http://dx.doi.org/10.1038/s41598-019-48344-5] [PMID: 31413326]
[19]
U.S. Food and Drug Administration. FDA Updates and Press Announcements on NDMA in Metformin. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin
[20]
U.S. Food and Drug Administration. Combined Direct Injection NNitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), and N-Nitrosodibutylamine (NDBA) Impurity Assay by GC-MS/MS. Available from: https://www.fda.gov/media/123409/download
[21]
United States Pharmacopeia. USP launches new standards, tools for detecting and controlling nitrosamine impurities in drug supply chain. Available from: https://www.usp.org/news/nitrosamines-impurities
[22]
Council of Europe. The EDQM’s response to nitrosamine contamination. Available from: https://www.edqm.eu/en/edqms-response-nitrosamine-contamination
[23]
Gaziano, T.A. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff. (Millwood), 2007, 26(1), 13-24.
[http://dx.doi.org/10.1377/hlthaff.26.1.13] [PMID: 17211010]
[24]
Prabhakaran, D.; Jeemon, P.; Roy, A. Cardiovascular diseases in India: Current epidemiology and future directions. Circulation, 2016, 133(16), 1605-1620.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.008729] [PMID: 27142605]
[25]
European pharmaceutical review. European Pharmacopoeia adopts a new chapter for the analysis of N-nitrosamine impurities. Available from: https://www.europeanpharmaceuticalreview.com/news/136053/european-pharmacopoeia-adopts-a-new-chapter-for-theanalysis-of-n-nitrosamine-impurities/ (Accessed on: February, 12 2021).
[26]
Nitrosamine impurities in human medicinal products Committee for Medicinal Products for Human Use. 2004.
[27]
Li, W.; Chen, N.; Zhao, Y.; Guo, W.; Muhammd, N.; Zhu, Y.; Huang, Z. Online coupling of Tandem liquid-phase extraction with HPLC-UV for the determination of trace: N -Nitrosamines in Food Products. Anal. Methods, 2018, 10(15), 1733-1739.
[http://dx.doi.org/10.1039/C8AY00014J]
[28]
Al-Kaseem, M.; Al-Assaf, Z.; Karabeet, F.A. Rapid, validated RP-HPLC method for the determination of seven volatile n-nitrosamines in meat. Pharmacol. Pharm., 2014, 05(3), 298-308.
[http://dx.doi.org/10.4236/pp.2014.53037]
[29]
Shabir, G.A. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J. Chrom. A, 2003, 57-66.
[http://dx.doi.org/10.1016/S0021-9673(02)01536-4]
[30]
Banerjee, S.; Mazumdar, S. Electrospray ionization mass spectrometry: A technique to access the information beyond the molecular weight of the analyte. Int. J. Anal. Chem., 2012, 2012, 282574-282540.
[http://dx.doi.org/10.1155/2012/282574] [PMID: 22611397]
[31]
Basics of LC/MS. Available from: https://www.agilent.com/cs/library/support/ documents/a05296.pdf
[32]
Sargent, M. Mass Spectrometry Ionization Methods. In: Guide to Achieving Reliable Quantitative LC-MS Measurements, 1st ed; RSC Analytical Methods Committee, 2013. Available from: http:// chemistryemory.edu/msc/tutorial/mass-spectrometry-ionization.html
[33]
Lee, J.H.; Lee, S.U.; Oh, J.E. Analysis of nine nitrosamines in water by combining automated solid-phase extraction with high-performance liquid chromatography-atmospheric pressure chemical ionisation tandem mass spectrometry. Int. J. Environ. Anal. Chem., 2013, 93(12), 1261-1273.
[http://dx.doi.org/10.1080/03067319.2013.803281]
[34]
Lindholm, P.C.; Knuutinen, J.S.; Ahkola, H.S.J.; Herve, S.H. Analysis of Pharmaceuticals. BioResources, 2014, 9, 3688-3732.
[35]
Topuz, E.; Aydin, E.; Pehlivanoglu-Mantas, E. A practical LC-MS/MS method for the detection of ndma at nanogram per liter concentra-tions in multiple water matrices. Water Air Soil Pollut., 2012, 223(9), 5793-5802.
[http://dx.doi.org/10.1007/s11270-012-1315-1]
[36]
Zeilmaker, M.J.; Bakker, M.I.; Schothorst, R.; Slob, W. Risk assessment of N-nitrosodimethylamine formed endogenously after fish-with-vegetable meals. Toxicol. Sci., 2010, 116(1), 323-335.
[http://dx.doi.org/10.1093/toxsci/kfq093] [PMID: 20351056]
[37]
Sörgel, F.; Kinzig, M.; Abdel-Tawab, M.; Bidmon, C.; Schreiber, A.; Ermel, S.; Wohlfart, J.; Besa, A.; Scherf-Clavel, O.; Holzgrabe, U. The contamination of valsartan and other sartans, part 1: New findings. J. Pharm. Biomed. Anal., 2019, 172(172), 395-405.
[http://dx.doi.org/10.1016/j.jpba.2019.05.022] [PMID: 31122801]
[38]
Scherf-Clavel, O.; Kinzig, M.; Besa, A.; Schreiber, A.; Bidmon, C.; Abdel-Tawab, M.; Wohlfart, J.; Sörgel, F.; Holzgrabe, U. The contami-nation of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities. J. Pharm. Biomed. Anal., 2019, 172(172), 278-284.
[http://dx.doi.org/10.1016/j.jpba.2019.04.035] [PMID: 31078064]
[39]
Method for the Determination of NDMA and NDEA by LCMS/MS in Sartans (Drug Substance and Film Coated Tablets). Available from: www.cvua-karlsruhe.de www.ua-bw.de
[40]
Guo, L.; Long, Z.; Leng, X. Rapid analysis of genotoxic nitrosamines by HPLC-MS/MS. Sciex, 2019. Available from: https://sciex.com/content/dam/SCIEX/pdf/tech-notes/all/Rapid-Analysis-of-Genotoxic-Nitrosamines-by-HPLC-MS-MS.pdf
[41]
Roux, J.L.; Gallard, H.; Croué, J.P.; Papot, S.; Deborde, M. NDMA formation by chloramination of ranitidine: Kinetics and mechanism. Environ. Sci. Technol., 2012, 46(20), 11095-11103.
[http://dx.doi.org/10.1021/es3023094] [PMID: 22967139]
[42]
Lv, J.; Wang, L.; Li, Y. Characterization of N-nitrosodimethyl-] amine formation from the ozonation of ranitidine. J. Environ. Sci. (China), 2017, 58, 116-126.
[http://dx.doi.org/10.1016/j.jes.2017.05.028] [PMID: 28774600]
[43]
Lv, J.; Li, Y.; Song, Y. Reinvestigation on the ozonation of N-nitrosodimethylamine: Influencing factors and degradation mechanism. Water Res., 2013, 47(14), 4993-5002.
[http://dx.doi.org/10.1016/j.watres.2013.05.035] [PMID: 23866137]
[44]
Ruddy, M.C.; Kostis, J.B. Angiotensin II receptor antagonists. Hypertension, 2005.
[http://dx.doi.org/10.1016/B978-0-7216-0258-5.50157-5]
[45]
Tsutsumi, T.; Akiyama, H.; Demizu, Y.; Uchiyama, N.; Masada, S.; Tsuji, G.; Arai, R.; Abe, Y.; Hakamatsuka, T.; Izutsu, K-I.; Goda, Y.; Okuda, H. Analysis of an impurity, N-nitrosodimethyl-] amine, in valsartan drug substances and associated products using GC-MS. Biol. Pharm. Bull., 2019, 42(4), 547-551.
[http://dx.doi.org/10.1248/bpb.b19-00006] [PMID: 30726781]
[46]
Determination of N-nitrosodimethylamine (NDMA) in metformin products by HRAM-GCMS PHARM NDMA EX_GC. 2020. Available from: https://www.hsa.gov.sg/docs/default-source/ announcements/safety-alerts/determination-of-ndma-in-metforminproducts- by-hram-gcms.pdf
[47]
New OMCL method for simultaneous determination of NDMA and NDEA in Sartan. Available from: https://www.edqm.eu/en/news/
[48]
Ad-Hoc Projects of the OMCL Network j EDQM - European Directorate for the Quality of Medicines. Available from: https://www.edqm. eu/en/ad-hoc-projects-omcl-network
[49]
Analysis of Nitrosamines in Sartan-Type Bulk Drug Substances. Available from: https://www.shimadzu.com/an/pharmaceutical lifescience/ndma.html

Rights & Permissions Print Cite
Article Metrics
33
3
© 2024 Bentham Science Publishers | Privacy Policy